738-70-5 Usage
Uses
Used in Human Medicine:
Trimethoprim is used as an antibiotic for the treatment of urinary tract infections, middle ear infections, and traveler's diarrhea. It is often combined with sulfamethoxazole, enhancing its antibacterial activity and broadening its spectrum. This combination is effective against a variety of Gram-positive and negative bacteria, including those that have developed resistance to other antibiotics.
Used in Veterinary Medicine:
Trimethoprim is used as a synergistic antimicrobial drug in veterinary medicine, particularly for treating avian sepsis caused by Escherichia coli, salmonellosis, fowl typhoid, cholera, and respiratory system secondary bacterial infections. It is also used for treating coccidiosis in poultry, where it acts as an anti-inflammatory and helps control inflammation associated with the infection.
Used as an Antibacterial Synergistic Drug:
Trimethoprim is used in combination with sulfonamide drugs to enhance antibacterial activity, with a general ratio of 1:5 for usage. This combination is effective in treating respiratory tract infections, urinary tract infections, and intestinal infections.
Used in Pneumocystis jiroveci Pneumonia Treatment:
Trimethoprim is also used to treat and prevent Pneumocystis jiroveci pneumonia, a severe lung infection that can be life-threatening, particularly in immunocompromised individuals.
Pyrimethamine class antibacterial agents
Trimethoprim is a lipophilic and weak alkaline pyrimethamine class bacteriostatic agent. It is a white or almost white crystalline powder, odorless, bitter, and slightly soluble in chloroform, ethanol or and acetone, but almost insoluble in water and highly soluble in glacial acetic acid solution. It has an antibacterial spectrum which is similar with sulfa drugs, but with a strong antibacterial effect. It has a good effect on treating Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Staphylococcus saprophyticus, and a variety of other gram-positive and negative bacteria. But it is ineffective against Pseudomonas aeruginosa infection. Its minimum inhibitory concentration is often less than 10 mg/L with using alone being easy to cause bacterial resistance, and thus it is generally not used alone, and mainly combined with sulfa drug to form compound preparation for clinical treatment of urinary tract infections, intestinal infections, respiratory infections, dysentery, enteritis, typhoid fever, meningitis, otitis media, meningitis, sepsis and soft tissue infections. It has an effect on treating typhoid and paratyphoid effect which is not less than ampicillin; It can also be combined with long-acting sulfa drugs for prevention and treatment of drug-resistant falciparum malaria.
The basic principle of anti-bacterial of trimethoprim is to interfere with folate metabolism in bacteria. The main mechanism of action is the selective inhibition of the activity of dihydrofolate reductase in bacteria so that dihydrofolate can’t be reduced to tetrahydrofolate. Since the synthesis of folic acid is the main part of a nucleic acid biosynthesis, and therefore the product prevents bacterial nucleic acids and proteins synthesis. Moreover, the binding affinity of trimethoprim (TMP) to bacterial dihydrofolate reductase enzyme is five times as strong as that to the mammalian dihydrofolate reductase. The combination between it with sulfa drugs can cause dual blockage to the folic acid biosynthesis metabolism of bacteria so that there is a synergistic effect which will enhance the antibacterial activity of sulfa drugs, and can turn antibacterial effect to bactericidal effect which reduce the drug-resistant strains. In addition, the product can also enhance the antibacterial effects of a variety of other antibiotics (such as tetracycline, gentamicin).
Side effects
Trimethoprim (referred to as the TMP) has a low toxicity with commonly used dose causing rare cases of adverse reactions. Since the product can interfere with folate metabolism which may cause patients’ suffer from some adverse reactions of blood systems such as anemia, leukopenia and thrombocytopenia. This is commonly observed in cases of overdose or long duration of application. Therefore, during the treatment, it is necessary to regularly check blood condition. This product has the maximum daily dosage being lower than 0.5g with continuous medication time being less than one week. Upon blood system adverse reaction, the patient can orally administrate folic acid preparation for treatment. This product is not suitable to be simultaneously combined with anticancer drugs, antiepileptic drugs and other folic acid antagonists used; the combination between TMP and SMZ or SD even can cause crystallization of urine. Other adverse reactions also include mild skin rash and gastrointestinal reactions.
Production methods
Use Trimethoxybenzaldehyde as raw material; first condense with methoxypropionitrile to produce 3'4'5'-trimethoxy-2-cyano-3-methoxy-propene; and cyclized together with guanidine nitrate in the presence of methanol/sodium methoxide.
Originator
Eusaprim,Wellcome,Italy,1970
Manufacturing Process
6 grams (0.26 mol) sodium was dissolved in 300 ml methanol under stirring
and refluxing. 47.5 grams (0.55 mol) β-methoxypropionitrile and 98 grams
(0.5 mol) 3,4,5-trimethoxybenzaldehyde were added and the mixture refluxed
gently for 4 hours. The mixture was then chilled and 150 ml of water was
added. The product crystallized rapidly. Crystallization was allowed to proceed
at 5° to 10°C under stirring for 1 hour. The product was filtered by suction
and washed on the filter with 200 ml of 60% ice cold methanol. The crude
material was air-dried and used for further steps without purification. It
melted at 78° to 80°C. A pure sample, recrystallized from methanol, melted
at 82°C. The yield of 3,4,5-trimethoxy-2'-methoxymethylcinnamonitrile was
92 grams, corresponding to 70% of the theory.
19 grams (0.83 mol) sodium was dissolved in 300 ml methanol, 106 grams of
3,4,5-trimethoxy-2'-methoxymethylcinnamonitrile was added and the mixture
gently refluxed for 24 hours. The solution, which had turned brown, was
poured into 1 liter of water and the precipitated oil extracted repeatedly with
benzene. The combined benzene layers (500 to 700 ml) were washed 3 times
with 500 ml of water, the benzene removed by evaporation in a vacuum from
a water bath, and the brown residual oil distilled in vacuo, boiling point 215°
to 225°C/11 mm. The clear, viscous oil, 3,4,5-trimethoxy-2'-cyano_x0002_dihydrocinnamaldehyde dimethyl acetal, weighed 83 grams (71% of the
theory), and showed a nD23 = 1.5230. It solidified upon standing. A sample
recrystallized from methanol melted at 69° to 70°C and showed a strong
melting point depression with the starting material; nD25 = 1.5190.
31.5 grams (0.107 mol) 3,4,5-trimethoxy-2'-cyano-dihydrocinnamaldehyde
dimethyl acetal was refluxed with methanolic guanidine solution (200 ml
containing 0.25 mol of guanidine) for 2 hours. The methanol completely
distilled off under stirring, finally from a bath of 110° to 120°C until the
residue solidified completely to a yellowish crystalline mass. After allowing to
cool, it was slurried with 100 ml of water and collected by vacuum filtration
and dried. The yield of 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine
amounted to 28 grams (91% of the theory). The material showed the correct
melting point of 199° to 200°C and was, however, yellowish discolored.
20 grams of the above product was added to 30 ml of 3 N aqueous sulfuric
acid at 60°C under stirring. The solution was chilled under stirring to 5° to
10°C. The crystalline sulfate was collected by vacuum filtration and washed on the filter twice with 10 ml of cold 3 N aqueous sulfuric acid each time. From
the filtrate there was recovered 1.3 grams (6.5%) of discolored material
melting at 195° to 196°C and which can be added to subsequent purification
batches.
The sulfate on the filter was dissolved in 200 ml of hot water, the solution
charcoaled hot, and the product precipitated from the clear colorless filtrate
by the gradual addition of a solution of 20 grams of sodium hydroxide in 40
ml of water under chilling. The precipitate was filtered by suction and washed
thoroughly with water on the filter. The white material, 17.5 grams (88%)
showed the correct melting point of 200° to 201°C, according to US Patent
3,341,541.
Antimicrobial activity
Trimethoprim has a broad spectrum of antimicrobial activity. It is 20–100 times more
active than sulfamethoxazole with respect to most bacterial forms. Trimethoprim is active
with respect to Gram-positive, aerobic bacteria such as Staphylococcus aureus,
Staphylococcus epidermidis, and various types of Streptococcus and Listeria monocytogenes. Trimethoprim is inferior to sulfonamides against forms of Nocardia. It is active with respect to Gram-negative, aerobic bacteria such as most E. coli, Enterobacter,
Proteus, Klebsiella, Providencia, Morganella, Serratia marcescens, Citrobacter,
Salmonella, Shigella, Yersinia enterocolitica that are sensitive to trimethoprim.
Trimethoprim is also active with respect to Legionella, Acinetobacter, Vibrio,
Aeromonas, Pseudomonas maltophila, P. cepacia, although P. aeruginosa is resistant to
trimethoprim.
Air & Water Reactions
Insoluble in water.
Reactivity Profile
Trimethoprim readily forms salts with acids. .
Fire Hazard
Flash point data for Trimethoprim are not available. Trimethoprim is probably combustible.
Biochem/physiol Actions
Inhibits the synthesis of tetrahydrofolate by procaryote specific dihydrofolate reductase (DHFR).
Mechanism of action
Haemophilus influenzae and H. ducreyi are sensitive to trimethoprim. Pathogenic
Neisseria (meningococci and gonococci) and Branhamella catarrhalis are moderately
resistant to trimethoprim, although they are very sensitive to a combination of trimethoprim and sulfamethoxazole. Anaerobic bacteria in general are resistant to trimethoprim,
although a combination of trimethoprim-sulfamethoxazole does have an effect on them.
Pneumocystis carinii is also sensitive to that combination.
Bacterial resistance to trimethoprim can originate because of a number of reasons:
inability of the drug to penetrate through the membrane (P. aeruginosa); the presence of
dihydrofolate reductase that is not sensitive to inhibition by trimethoprim; overproduction
of dihydrofolate reductase and mutation expressed as thyminic dependence, when the
organism requires exogenic thymine for synthesizing DNA, i.e. bypassing metabolic
blockage caused by trimethoprim.
Resistance to a combination of trimethoprim-sulfamethoxazole is always less frequent
than when any of these drugs is used separately. This combination of drugs, which is
known by the commercial names cotrimoxazole, bactrim, biseptol, sulfatrim, and many
others, is used for treating infections of the respiratory tract, infections of the urinary tract,
gastric infections, surgical infections, enteritis, meningitis, and other diseases.
Clinical Use
Trimethoprim (5-[(3,4,5-trimethoxyphenyl)methyl]-2,4-pyrimidinediamine or 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine) is closely related to several antimalarialsbut does not have good antimalarial activity by itself; it is,however, a potent antibacterial. Originally introduced incombination with sulfamethoxazole, it is now available as asingle agent.Approved by the FDA in 1980, trimethoprim as a singleagent is used only for the treatment of uncomplicatedurinary tract infections. The argument for trimethoprim asa single agent was summarized in 1979 by Wormser andDeutsch. They point out that several studies comparingtrimethoprim with TMP–SMX for the treatment ofchronic urinary tract infections found no statistically relevantdifference between the two courses of therapy.The concern is that when used as a single agent, bacterianow susceptible to trimethoprim will rapidly developresistance. In combination with a sulfonamide, however,the bacteria will be less likely to do so. That is, they willnot survive long enough to easily develop resistance toboth drugs.
Synthesis
Trimethoprim, 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine (33.1. 51), is synthesized in various ways. The first scheme of synthesis begins with ethyl ester of 3,4,5-trimethoxydehydrocinnamic acid, which is formylated with ethyl formate using sodium as a base to make an enol of the semialdehyde 3,4,5-trimethoxybenzylmalonic ester (33.1.49), which undergoes a heterocyclization reaction with guanidine to make 2-amino- 4-hydroxy-5-(3,4,5-trimethoxybenzyl)pyrimidine (33.1.50). Subsequent replacement of the hydroxyl group in the resulting product with chlorine using phosphorous oxychloride and then with an amino group using ammonia gives the desired trimethoprim.
All of the other syntheses begin with 3,4,5-trimethoxybenzaldehyde. According to one of them, condensation of 3,4,5-trimethoxybenzaldehyde with 3-ethoxy- or 3-anilinopropionitrile gives the corresponding benzylidene derivative (33.1.52), which upon direct reaction with guanidine gives trimethoprim.
Trimethoprim has also been synthesized by condensing 3,4,5-trimethoxybenzaldehyde with malonic acid dinitrile in a Knoevenagel reaction, which forms the derivative (33.1.53), which is partially reduced to the enamine (33.1.54) by hydrogen using a palladium on carbon catalyst, which upon being reacted with guanidine is transformed into trimethoprim.
Finally, trimethoprim can be synthesized in a manner that also uses a Knoevenagel condensation of 3,4,5-trimethoxybenzaldehyde as the first step, but this time with ethyl cyanoacetate, which gives an ylidene derivative (33.1.55). The double bond in this product is reduced by hydrogen over a palladium on carbon catalyst, giving 3,4,5-trimethoxybenzylcyanoacetic ester (33.1.56). Reacting this in a heterocyclization reaction with guanidine gives the desired trimethoprim.
Drug interactions
Potentially hazardous interactions with other drugs
Anti-arrhythmics: increased risk of ventricular
arrhythmias with amiodarone - avoid; concentration
of procainamide increased.
Antiepileptics: antifolate effect and concentration of
fosphenytoin and phenytoin increased.
Antimalarials: increased risk of antifolate effect with
pyrimethamine.
Ciclosporin: increased risk of nephrotoxicity;
concentration of ciclosporin reduced by IV
trimethoprim.
Cytotoxics: increased risk of haematological
toxicity with azathioprine, methotrexate and
mercaptopurine; antifolate effect of methotrexate
increased.
Tacrolimus: possible increased risk of nephrotoxicity.
Metabolism
About 10 to 20% of trimethoprim is metabolised in the liver and small amounts are excreted in the faeces via the bile, but most, about 40 to 60% of a dose, is excreted in urine, mainly as unchanged drug. Trimethoprim is excreted mainly by the kidneys through glomerular filtration and tubular secretion.
Check Digit Verification of cas no
The CAS Registry Mumber 738-70-5 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 7,3 and 8 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 738-70:
(5*7)+(4*3)+(3*8)+(2*7)+(1*0)=85
85 % 10 = 5
So 738-70-5 is a valid CAS Registry Number.
InChI:InChI=1/C14H18N4O3/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15/h5-7H,4H2,1-3H3,(H4,15,16,17,18)
738-70-5Relevant articles and documents
Nano Ag/AgCl wires-photocatalyzed hydrogen production and transfer hydrogenation of Knoevenagel-type products
Attia, Yasser A.,Mohamed, Yasser M. A.
, p. 1677 - 1686 (2022/02/05)
An investigation of the relationship between the morphology of Ag/AgCl nanostructured composites with their catalytic performance has been reported. The concentration ratio of silver nitrate and hydrochloric acid was controlled to produce Ag/AgCl nanowires (NWs) and nanospheres (NSs). The catalytic activity of the photoresponsive NWs was evaluated towards methylene blue (MB) dye degradation and hydrogen production and showed high performance compared to the NSs under visible light irradiation. It was estimated that the NWs produced hydrogen at a rate approximately 2.27 times faster than the NSs. Additionally, the catalytic properties of the as-synthesized nanomaterials were examined in the transfer hydrogenation of the carbon-carbon double bonds (CC) present in Knoevenagel-type products (trisubstituted alkenes) through exciting the surface plasmons of the NWs and NSs with a catalyst loading of 5 wt% under visible light irradiation. Again, it was revealed that the Ag/AgCl NWs showed increased activity to produce the reduced adducts in a higher yield, with a 95% isolated yield compared to that obtained in the case of the use of Ag/AgCl NSs, which afforded products in a 62% isolated yield. Further investigation was carried on the catalytic performance of the Ag/AgCl NWs in the one-pot synthesis of trimethoprim, a known antibiotic, which was afforded in an 86% yield through two consecutive steps in a tandem process. It was clearly shown from the results that the photocatalytic activity of the prepared Ag/AgCl nanoparticles depends on their morphology. This journal is
METHODS AND COMPOSITIONS FOR OPTOCHEMICAL CONTROL OF CRISPR-CAS9
-
Paragraph 0044, (2021/10/15)
The disclosure includes non-naturally occurring or engineered DNA- or RNA-guided nuclease systems, comprising CRISPR enzymes associated with at least one destabilization domain (DD) and photocaged stabilization ligands with at least one photocage molecule, along with compositions, systems and complexes involving such systems, nucleic acid molecules and vectors encoding the same, delivery systems involving the same, uses thereof.
A Singular System with Precise Dosing and Spatiotemporal Control of CRISPR-Cas9
Manna, Debasish,Maji, Basudeb,Gangopadhyay, Soumyashree A.,Cox, Kurt J.,Zhou, Qingxuan,Law, Benjamin K.,Mazitschek, Ralph,Choudhary, Amit
, p. 6285 - 6289 (2019/04/08)
Several genome engineering applications of CRISPR-Cas9, an RNA-guided DNA endonuclease, require precision control of Cas9 activity over dosage, timing, and targeted site in an organism. While some control of Cas9 activity over dose and time have been achieved using small molecules, and spatial control using light, no singular system with control over all the three attributes exists. Furthermore, the reported small-molecule systems lack wide dynamic range, have background activity in the absence of the small-molecule controller, and are not biologically inert, while the optogenetic systems require prolonged exposure to high-intensity light. We previously reported a small-molecule-controlled Cas9 system with some dosage and temporal control. By photocaging this Cas9 activator to render it biologically inert and photoactivatable, and employing next-generation protein engineering approaches, we have built a system with a wide dynamic range, low background, and fast photoactivation using a low-intensity light while rendering the small-molecule activator biologically inert. We anticipate these precision controls will propel the development of practical applications of Cas9.
Synthetic method of trimethoprim
-
, (2016/10/08)
The invention discloses a synthetic method of trimethoprim. Trimethoprim is synthesized from 3,4,5-trimethoxybenzaldehyde and ethyl cyanoacetate. The method has the advantages of high conversion rate, short time, and industrial production facilitation.
Practical preparation of trimethoprim: A classical antibacterial agent
Ji, Ya-Fei,Jiang, Jian-An,Liu, Hong-Wei,Liao, Dao-Hua,Wei, Xian-Yong
, p. 1517 - 1522 (2013/05/22)
An efficient, simple, and mild preparation of the classical antibacterial agent trimethoprim (1) was achieved in 85% overall yield from 3,4,5-trimethoxybenzaldehyde (2). First, the addition of propenenitrile (3) with dimethylamine almost quantitatively afforded 3-dimethylaminopropanenitrile (7). Then, by condensation of 7 with 2 as well as the continuous replacement of 3-dimethylamino group with aniline in situ, the key intermediate 3-anilino-2-(3,4,5-trimethoxybenzyl)propenenitrile (9) was obtained in an excellent yield of 91% with a one-pot procedure. Finally, the cyclization of 9 with guanidine nitrate furnished 1 in yields as good as 95% in the presence of the excessive sodium methoxide. Supplemental materials are available for this article. Go to the publisher's online edition of Synthetic Communications1 to view the free supplemental file. Copyright Taylor & Francis Group, LLC.
Immobilization of malarial (Plasmodium falciparum) dihydrofolate reductase for the selection of tight-binding inhibitors from combinatorial library
Thongpanchang, Chawanee,Taweechai, Supannee,Kamchonwongpaisan, Sumalee,Yuthavong, Yongyuth,Thebtaranonth, Yodhathai
, p. 5006 - 5012 (2008/02/08)
A simple procedure for selection of tight-binding inhibitors of mutant dihydrofolate reductases from Plasmodium falciparum (PfDHFRs) based on preferential binding to the enzyme immobilized on a Sepharose column has been described. PfDHFRs with a cysteine residue at the C-terminal have been prepared in order to immobilize to a thiopropyl-Sepharose gel via S-S linkage. The amount of immobilized DHFRs was estimated to be 4-5 mg/g of dried gel, and the activities of bound DHFRs were comparable to that of free enzymes. The prepared immobilized enzyme has been used for the selection of tight-binding inhibitors from combinatorial libraries, based on the affinities of each ligand with the enzyme. Free ligands were then identified and analyzed quantitatively by high-performance liquid chromatography-mass spectrometry, and the components with high binding affinity of the library could thus be realized. Results could be confirmed by quantitative analysis of the bound ligands released from the enzyme by guanidine hydrochloride treatment.
Synthesis of functionalized diarylmethanes via a copper-catalyzed cross-coupling of arylmagnesium reagents with benzylic phosphates
Kofink, Christiane C.,Knochel, Paul
, p. 4121 - 4124 (2007/10/03)
A combination of copper chloride, triethyl phosphite, and tetrabutylammonium iodide is a very efficient catalytic system for the synthesis of polyfunctionalized diarylmethanes, using the cross-coupling reaction of arylmagnesium halides with benzylic phosphates. The antibiotic Trimethoprim has been prepared using this Cu(I)-catalyzed cross-coupling in 52% overall yield (four steps).
Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine resistant Plasmodium falciparum
Tarnchompoo, Bongkoch,Sirichaiwat, Chawanee,Phupong, Worrapong,Intaraudom, Chakapong,Sirawaraporn, Worachart,Kamchonwongpaisan, Sumalee,Vanichtanankul, Jarunee,Thebtaranonth, Yodhathai,Yuthavong, Yongyuth
, p. 1244 - 1252 (2007/10/03)
The reduced binding of pyrimethamine to Serl08Asn (S108N) mutants of parasite dihydrofolate reductase (DHFR), which forms the basis of resistance of Plasmodium falciparum to pyrimethamine, is largely due to steric constraint imposed by the bulky side chain of N108 on Cl of the 5-p-Cl-phenyl group. This and other S108 mutants with bulky side chains all showed reduced binding to pyrimethamine and cycloguanil. Less effect on binding to some bulky mutants was observed for trimethoprim, with greater flexibility for the 5-substituent. S108N DHFR also binds poorly with other pyrimethamine derivatives with bulky groups in place of the p-Cl, and the binding was generally progressively poorer for the double (C59R+S108N) mutant. Removal of the p-Cl or replacement with m-Cl led to better binding with the mutant DHFRs. Pyrimethamine analogues with unbranched hydrophobic 6-substituents showed generally good binding with the mutant DHFRs. A number of compounds were identified with high affinities for both wild-type and mutant DHFRs, with very low to no affinity to human DHFR. Some of these compounds show good antimalarial activities against pyrimethamine-resistant P. falciparum containing the mutant DHFRs with low cytotoxicity to three mammalian cell lines.
An efficient benzyltriethylammonium chloride catalysed preparation of electrophilic alkenes: a practical synthesis of trimethoprim
Bose, D. Subhas,Narsaiah, A. Venkat
, p. 36 - 38 (2007/10/03)
The Knoevenagel condensation of carbonyl compounds with active methylene compounds was readily carried out with benzyltriethylammonium chloride as a catalytic agent, under solvent-free conditions to produce olefinic products in high yeilds: the scope of this protocol is utilised for the synthesis of the antibacterial agent trimethoprim.
A New Route To Antibacterial Trimethoprim
Harada, Kenichi,Choshi, Tominari,Sugino, Eiichi,Sato, Kohichi,Hibino, Satoshi
, p. 1119 - 1126 (2007/10/02)
3-Methylthio-2-(3',4',5'-trimethoxybenzyl)acrylonitrile (6) derived from 3,4,5-trimethoxyphenylacetaldehyde (2) in a four step sequence was utilized as a new three carbon unit of trimethoprim (1).
